Hohimer Wealth Management LLC Purchases 1,445 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Hohimer Wealth Management LLC grew its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 1.0% in the third quarter, HoldingsChannel.com reports. The fund owned 145,357 shares of the biopharmaceutical company’s stock after acquiring an additional 1,445 shares during the quarter. Hohimer Wealth Management LLC’s holdings in Royalty Pharma were worth $4,112,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the business. Swedbank AB lifted its position in shares of Royalty Pharma by 30.6% during the 2nd quarter. Swedbank AB now owns 10,813,470 shares of the biopharmaceutical company’s stock valued at $285,151,000 after acquiring an additional 2,533,570 shares during the period. Van ECK Associates Corp increased its stake in Royalty Pharma by 171.1% in the third quarter. Van ECK Associates Corp now owns 101,500 shares of the biopharmaceutical company’s stock valued at $2,777,000 after purchasing an additional 64,057 shares in the last quarter. Summit Global Investments acquired a new position in shares of Royalty Pharma during the third quarter valued at about $735,000. New South Capital Management Inc. boosted its position in shares of Royalty Pharma by 5.0% during the 3rd quarter. New South Capital Management Inc. now owns 2,466,371 shares of the biopharmaceutical company’s stock worth $69,774,000 after purchasing an additional 117,394 shares in the last quarter. Finally, Two Sigma Advisers LP grew its stake in shares of Royalty Pharma by 44.7% in the 3rd quarter. Two Sigma Advisers LP now owns 3,033,200 shares of the biopharmaceutical company’s stock valued at $85,809,000 after buying an additional 936,900 shares during the period. 54.35% of the stock is owned by institutional investors.

Royalty Pharma Stock Performance

Shares of RPRX opened at $25.59 on Wednesday. The firm has a market capitalization of $15.08 billion, a P/E ratio of 13.26, a P/E/G ratio of 4.55 and a beta of 0.46. Royalty Pharma plc has a 52 week low of $25.10 and a 52 week high of $31.66. The stock has a 50 day moving average price of $26.88 and a two-hundred day moving average price of $27.26. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.54 and a current ratio of 1.54.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 10th. Investors of record on Friday, November 15th were issued a dividend of $0.21 per share. The ex-dividend date was Friday, November 15th. This represents a $0.84 annualized dividend and a yield of 3.28%. Royalty Pharma’s dividend payout ratio (DPR) is currently 43.52%.

Wall Street Analyst Weigh In

RPRX has been the topic of a number of research reports. The Goldman Sachs Group upped their price target on Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Citigroup lowered their target price on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Finally, StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Royalty Pharma has a consensus rating of “Moderate Buy” and an average target price of $41.67.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.